Children with uncontrolled, moderate to severe asthma used dupilumab or placebo for 52 weeks. The treatment group had significant decreases in annualized exacerbation rates compared with the ...

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

The committee concluded that dupilumab does not represent a cost-effective use of resources, so could not be recommended for treating severe asthma with type 2 inflammation.

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

Roshni Naik, MD, allergist at Mount Sinai Health System, discusses the results after treating a case of severe asthma with nasal polyps: "After five months of starting Dupilumab frequency of ...

For COPD patients, the adage holds true: "the first way to get out of a hole is to quit digging one," said Christopher Mosher ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.

Patients with atopic dermatitis had an increased risk for COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.